SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (14649)9/16/2000 9:10:22 PM
From: Cacaito  Read Replies (3) | Respond to of 17367
 
Again, no excess death, cause there is not proven decrease in mortality, even the probability of it is less now, cause it was a more striking difference in the pII with historical controls, now you have available "the largest data collected in this disorder" clearly showing no difference.

Bax could commit itself for the kids, and xoma, and with good $100 to $200 they could do a very good trial in Africa, plenty of subjects, not even need for individual informed consent, institutional one is accepted in Africa, immediate oral consent as minimal requirement pre or post use is possible. And this is FACT.

All the efforts to baxoma, show the money!



To: Robert K. who wrote (14649)9/16/2000 11:18:38 PM
From: aknahow  Read Replies (2) | Respond to of 17367
 
Cacaito, with all the banter going back and forth you seem to use the phrase underpowered study but never go back to the fact stated in the article that the 6 hour delay was a major factor in the trial becoming underpowered as by the time 6 additional hours had past much of the damage by endotoxin had already been done.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News